Handlogten M E, Huang C, Shiraishi N, Awata H, Miller R T
Division of Nephrology, Department of Medicine, University of Florida, Gainesville, Florida 32610, USA.
J Biol Chem. 2001 Apr 27;276(17):13941-8. doi: 10.1074/jbc.M007306200. Epub 2001 Jan 18.
The Ca(2+)-sensing receptor (CaR) stimulates a number of phospholipase activities, but the specific phospholipases and the mechanisms by which the CaR activates them are not defined. We investigated regulation of phospholipase A(2) (PLA(2)) by the Ca(2+)-sensing receptor (CaR) in human embryonic kidney 293 cells that express either the wild-type receptor or a nonfunctional mutant (R796W) CaR. The PLA(2) activity was attributable to cytosolic PLA(2) (cPLA(2)) based on its inhibition by arachidonyl trifluoromethyl ketone, lack of inhibition by bromoenol lactone, and enhancement of the CaR-stimulated phospholipase activity by coexpression of a cDNA encoding the 85-kDa human cPLA(2). No CaR-stimulated cPLA(2) activity was found in the cells that expressed the mutant CaR. Pertussis toxin treatment had a minimal effect on CaR-stimulated arachidonic acid release and the CaR-stimulated rise in intracellular Ca(2+) (Ca(2+)(i)), whereas inhibition of phospholipase C (PLC) with completely inhibited CaR-stimulated PLC and cPLA(2) activities. CaR-stimulated PLC activity was inhibited by expression of RGS4, an RGS (Regulator of G protein Signaling) protein that inhibits Galpha(q) activity. CaR-stimulated cPLA(2) activity was inhibited 80% by chelation of extracellular Ca(2+) and depletion of intracellular Ca(2+) with EGTA and inhibited 90% by treatment with W7, a calmodulin inhibitor, or with KN-93, an inhibitor of Ca(2+), calmodulin-dependent protein kinases. Chemical inhibitors of the ERK activator, MEK, and a dominant negative MEK, MEK(K97R), had no effect on CaR-stimulated cPLA(2) activity but inhibited CaR-stimulated ERK activity. These results demonstrate that the CaR activates cPLA(2) via a Galpha(q), PLC, Ca(2+)-CaM, and calmodulin-dependent protein kinase-dependent pathway that is independent the ERK pathway.
钙敏感受体(CaR)可刺激多种磷脂酶活性,但具体涉及哪些磷脂酶以及CaR激活它们的机制尚不清楚。我们研究了在表达野生型受体或无功能突变体(R796W)CaR的人胚肾293细胞中,钙敏感受体(CaR)对磷脂酶A2(PLA2)的调节作用。基于花生四烯酰三氟甲基酮对其的抑制作用、溴代烯醇内酯对其无抑制作用以及通过共表达编码85 kDa人胞质型PLA2(cPLA2)的cDNA增强CaR刺激的磷脂酶活性,PLA2活性归因于胞质型PLA2(cPLA2)。在表达突变型CaR的细胞中未发现CaR刺激的cPLA2活性。百日咳毒素处理对CaR刺激的花生四烯酸释放和CaR刺激的细胞内钙(Ca2+)升高(Ca2+(i))影响极小,而用完全抑制CaR刺激的磷脂酶C(PLC)和cPLA2活性。CaR刺激的PLC活性受到RGS4表达的抑制,RGS4是一种抑制Gαq活性的RGS(G蛋白信号调节剂)蛋白。通过用EGTA螯合细胞外Ca2+和耗尽细胞内Ca2+,CaR刺激的cPLA2活性被抑制80%,用钙调蛋白抑制剂W7或Ca2+、钙调蛋白依赖性蛋白激酶抑制剂KN - 93处理可抑制90%。ERK激活剂MEK的化学抑制剂和显性负性MEK(MEK(K97R))对CaR刺激的cPLA2活性无影响,但抑制CaR刺激的ERK活性。这些结果表明,CaR通过一条独立于ERK途径的Gαq、PLC、Ca2+ - CaM和钙调蛋白依赖性蛋白激酶依赖性途径激活cPLA2。